People with systemic lupus erythematosus (SLE) have vitamin D deficiency — and living in Asia, South America, or Africa are among the risk factors, according to a review study. Not receiving vitamin D supplements also is a risk factor increasing this deficiency, the findings showed. The research, “…
News
Patients with systemic lupus erythematosus (SLE) who attain a low disease state have a lower risk of subsequent disease flares and accumulated organ damage, making this state a potential treatment target in clinical trials, a new study suggests. The research was published in an article, “Lupus low disease…
Low-dose use of a treatment for certain advanced cancers, aldesleukin, was well-tolerated and lessened disease activity in people with refractory systemic lupus erythematosus (SLE) taking part in a small Phase 1/2a trial. Study results also showed patients had higher proportions of a subset of immune T-cells associated with suppression…
In support of projects in several areas of lupus research, the Lupus Foundation of America has awarded four investigators — two more  than in prior years — with the Gary S. Gilkeson Career Development Award (CDA). The award is meant for fellows and clinicians at the early stages of…
PredictImmune is planning to expand its pipeline with the development of new strategies to support personalized care for people with systemic lupus erythematosus (SLE) and other inflammatory diseases. This follows the U.K.-based company’s acquisition of worldwide licensing rights over Cambridge Enterprise’s algorithms and software. The new deal…
Researchers, in collaboration with the World Health Organization (WHO), have established a new reference standard for anti-dsDNA autoantibodies — one of the hallmarks of systemic lupus erythematosus (SLE) — to help standardize laboratory analysis and improve diagnosis and treatment of lupus worldwide. The study, “A WHO…
The Committee for Medicinal Products for Human Use (CHMP), an arm of the European Medicines Agency (EMA), recommended the approval of Benlysta (belimumab) as an add-on therapy for children age 5 and older with systemic lupus erythematosus (SLE) and high disease activity. The European Commission will…
Aiming to raise disease awareness and research funds, the Lupus Foundation of America’s (LFA) Walk to End Lupus Now hits Los Angeles on Sept. 28. Taking place at the LA Live complex, the 1.33-mile event will again feature actress Kate Linder of television’s “The Young and…
The U.S. Food and Drug Administration (FDA) has granted the designation of breakthrough therapy to Gazyva (obinutuzumab) for the treatment of adult patients with lupus nephritis, a life-threatening kidney inflammation. The breakthrough designation is given to medications that…
Reactivation of the Epstein-Barr virus (EBV) may result in systemic lupus erythematosus (SLE) in at-risk individuals, according to a study in relatives of SLE patients. The findings also revealed that gene variants previously associated with EBV infection are implicated in the risk of developing SLE. The research, “…
Recent Posts
- AMETHYST trial of litifilimab making “strong progress,” Biogen says
- What reasonable workplace accommodations actually look like
- How to mitigate the sense of failure that can arise during a lupus flare
- What to remember if you’re dating with a chronic illness
- Finding our superpower by surviving lupus flares